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Abstract
Objectives To compare the diagnostic accuracy of preoperative 18F-FDG PET/CT and MRI tumor markers for prediction of
lymph node metastases (LNM) and aggressive disease in endometrial cancer (EC).
Methods Preoperative whole-body 18F-FDG PET/CT and pelvic MRI were performed in 215 consecutive patients with histo-
logically confirmed EC. PET/CT-based tumor standardized uptake value (SUVmax and SUVmean), metabolic tumor volume
(MTV), and PET-positive lymph nodes (LNs) (SUVmax > 2.5) were analyzed together with the MRI-based tumor volume
(VMRI), mean apparent diffusion coefficient (ADCmean), and MRI-positive LN (maximum short-axis diameter ≥ 10 mm).
Imaging parameters were explored in relation to surgicopathological stage and tumor grade. Receiver operating characteristic
(ROC) curves were generated yielding optimal cutoff values for imaging parameters, and regression analyses were used to assess
their diagnostic performance for prediction of LNM and progression-free survival.
Results For prediction of LNM, MTV yielded the largest area under the ROC curve (AUC) (AUC= 0.80), whereas VMRI had
lower AUC (AUC = 0.72) (p = 0.03). Furthermore, MTV > 27 ml yielded significantly higher specificity (74%, p < 0.001) and
accuracy (75%, p < 0.001) and also higher odds ratio (12.2) for predicting LNM, compared with VMRI > 10 ml (58%, 62%, and
9.7, respectively). MTV > 27ml also tended to yield higher sensitivity than PET-positive LN (81% vs 50%, p = 0.13). Both VMRI
> 10 ml and MTV > 27 ml were significantly associated with reduced progression-free survival.
Conclusions Tumor markers from 18F-FDG PET/CToutperformMRImarkers for the prediction of LNM.MTV > 27ml yields a
high diagnostic performance for predicting aggressive disease and represents a promising supplement to conventional PET/CT
reading in EC.
Key Points
• Metabolic tumor volume (MTV) outperforms other 18F-FDG PET/CT and MRI markers for preoperative prediction of lymph
node metastases (LNM) in endometrial cancer patients.
•Using cutoff values for tumor volume for prediction of LNM,MTV>27ml yielded higher specificity and accuracy than VMRI > 10 ml.
• MTV represents a promising supplement to conventional PET/CT reading for predicting aggressive disease in EC.
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Abbreviations
18F-FDG Fluorine-18 fluorodeoxyglucose
ADC Apparent diffusion coefficient
CE Contrast-enhanced
CI Cervical stroma invasion
DMI Deep myometrial invasion
FIGO The International Federation of Gynecology and
Obstetrics system
LNM Lymph node metastases
MRI Magnetic resonance imaging
MTV Metabolic tumor volume
PET/CT Positron emission tomography/computed
tomography
SLND Sentinel lymph node dissection
SUV Standardized uptake value
VMRI Tumor volume measured on MRI
Introduction
Endometrial cancer is the sixth most common cancer among
women worldwide, and the incidence has been steadily increas-
ing over the past decades [1]. Endometrial tumors are histolog-
ically classified as non-endometrioid subtype or endometrioid
subtype (grades 1–3), and non-endometrioid subtype and grade
3 endometrioid subtype are associated with high-risk disease
[2]. Endometrial cancer is surgicopathologically staged accord-
ing to The International Federation of Gynecology and
Obstetrics (FIGO) system, with evaluation of tumor extent
and lymph node involvement [3]. Presence of lymph node me-
tastases (LNM) implies poorer prognosis, and the preoperative
identification of patients at high risk of having LNM may be
useful for tailoring lymphadenectomy and subsequent adjuvant
therapy. Routine lymphadenectomy is controversial due to lack
of evidence supporting that this improves survival [4–6],
paralleled by well-known side effects from lymphadenectomy
with resulting reduced quality of life. Preventing surgical over-
and under-treatment by tailoring lymphadenectomy only to pa-
tients at high risk of extrauterine disease, is thus crucial if im-
proved endometrial cancer patient care is to be achieved.
Different predictionmodels for LNM in endometrial cancer
have been suggested. Some models are inherently postopera-
tive since they are based on tumor biomarker profiles derived
from hysterectomy specimens [7–9], whereas proposed pre-
operative models combine preoperative imaging characteris-
tics and biopsy/curettage and serum markers, e.g., cancer an-
tigen (CA 125) [10–12]. When applied in independent patient
cohorts, these models have been shown to have variable fea-
sibilities [13–15], and at present, the best risk stratification
model in endometrial cancer is not yet defined, and no uni-
form risk model is routinely used across centers. Furthermore,
sentinel lymph node dissection (SLND) procedures have been
increasingly advocated as a feasible alternative to full
lymphadenectomy in endometrial cancer patients. However,
how to select patient groups that are likely to benefit from
SLND and how the procedure is optimally performed are
not yet fully known [2, 16, 17].
Contrast-enhanced (CE) magnetic resonance imaging
(MRI) has long been considered the radiological imaging
method of choice for preoperative assessment of local tumor
stage in endometrial cancer (i.e., the identification of deep
myometrial invasion, cervical stroma invasion, and pelvic
LNM). However, the reported diagnostic staging performance
of CE MRI has a broad range and well-known limitations in
particular for diagnosing LNM [18]. Preoperative 18F
fluorodeoxyglucose (18F-FDG) positron emission tomogra-
phy combined with computed tomography (PET/CT) is in-
creasingly used for staging of various cancers, including en-
dometrial cancer. Several studies on small- to medium-sized
cohorts have reported a high diagnostic performance of 18F-
FDG PET/CT in endometrial cancer, especially for detecting
LNM [19–23].
The primary objectives of this study were to assess and
compare the diagnostic accuracy of preoperative 18F-FDG
PET/CT- and MRI-derived markers for the prediction of
LNM and aggressive disease in a large endometrial cancer
patient cohort. Furthermore, this study aimed to explore how
metabolic tumor parameters from 18F-FDG PET/CT- and
MRI-based tumor markers are interrelated.
Materials and methods
Patient series and study setting
This retrospective cohort study was conducted under institu-
tional review board (IRB)–approved protocols with written
informed consent from all patients. Preoperative pelvic MRI
and whole-body 18F-FDG PET/CT were performed from
October 2011 to December 2016 in all patients, n = 215, with
histologically confirmed endometrial carcinoma at surgery.
All patients had a single primary tumor. Mean (range) time
span between MRI and 18F-FDG PET/CTwas 4 (0–38) days.
Themean (range) time interval betweenMRI examination and
primary treatment was 16 (0–98) days and between PET/CT
and primary treatment 16 (0–102) days. The shortest interval
(zero days) between preoperative imaging and treatment was
recorded in two patients having inoperable disease (FIGO IV)
who started chemotherapy at the day of the imaging examina-
tion. All patients were diagnosed and treated at the same uni-
versity hospital serving a population of ~ 1 million inhabi-
tants. Clinical data (e.g., age, menopausal status, height, body
weight) were registered, and patients were staged according to
the FIGO 2009 criteria [3]. Depths of myometrial invasion
(MI), cervical stroma invasion (CI), and lymph node metasta-
ses (LNM) were evaluated by the pathologists using standard
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procedures. Patient follow-up data have been collected from
patient records and from correspondence with the responsible
physicians/gynecologists. For patients considered radically
treated (203/215 patients), standard-of-care follow-up is clin-
ical examinations quarterly during the first 2 years and bian-
nually until 5 years after primary diagnosis. For patients not
considered radically treated (12/215 patients), the follow-up is
individualized, normally with frequent follow-ups. Mean
(range) follow-up time for survivors was 33 (0–66) months
and date of last follow-up was 16 August 2018. Progression
was defined as local recurrence/progression in the pelvis or
new metastases in the abdomen or at distant locations.
MRI protocol and image analysis
Pelvic MRI was acquired on a Siemens Avanto 1.5-T scanner
for 156/215 patient and on a Siemens Skyra 3-T scanner for
the remaining 59/215 patients. Prior to imaging, 20 mg
butylscopolamine bromide (Buscopan, Boehringer
Ingelheim) was administered intravenously to reduce bowel
peristalsis. The MRI protocol included sagittal and axial
oblique (perpendicular to the long axis of the uterus) T2-
weighted images and axial oblique T1-weighted gradient-ech-
o images before and 2 min after administration of 0.1 mmol
gadolinium/kg body weight (Dotarem, Guerbet). Diffusion-
weighted imaging (DWI) was performed using an axial
oblique 2D echo-planar imaging sequence with b values of 0
and 1000 s/mm2, and apparent diffusion coefficient (ADC)
maps were generated. Information on 1.5-T and 3-T scanner
protocols are given in Suppl. Table 1.
The de-identified MRI images were evaluated by three ra-
diologists with 2–10 years of experience, who were blinded to
clinical data, tumor stage, and patient outcome. Maximum
tumor diameter was measured in three orthogonal planes:
anteroposterior (AP) and transverse (TV) diameters on CE
paraxial T1-weighted images and the craniocaudal (CC) tu-
mor diameter on sagittal T2-weighted images (Fig. 1). Tumor
volume (VMRI) was estimated by assuming the shape of an
ellipsoid: VMRI = 4/3π(AP/2 × TV/2 ×CC/2). In addition, for a
subgroup of 60 patients (randomly selected), 3D tumor masks
were outlined by one of the radiologists (JAD) in order to
compare the MRI tumor volume estimated by the ellipsoid
method with a supposedly more exact 3D tumor volume mea-
surement. MRI findings suggesting deep (≥ 50%) myometrial
invasion (DMI) and pelvic or paraaortic LNM (MRI-positive
lymph nodes (LN), defined as enlarged LN with a maximum
short-axis diameter of ≥ 10 mm) were recorded by all three
readers. Since this study was focused on patient-based analy-
sis, the number, shape, and position of the enlarged LNs were
(although registered) not taken into account for prediction of
LNM at surgical staging. The mean tumor apparent diffusion
coefficient (ADCmean) was measured in a region of interest
(ROI) drawn in the ADC map depicting the largest cross-
sectional tumor diameter. Consensus values for the three
readers were established using the median value for continu-
ous variables and the majority reading for categorical
variables.
18F-FDG PET/CT imaging protocol and image analysis
18F-FDG PET/CTwas performed on a Siemens Biograph 40
True Point scanner, with scan range coverage from the skull
base to the mid-thigh. All patients were instructed to fast for
6 h prior to scanning and had an i.v. injection of 4.6MBq 18F-
FDG/kg body weight or 370 MBq 18F-FDG approximately
60 min prior to scanning. The PET images were acquired with
3 min per bed position and reconstructed with correction for
scatter and attenuation based on the CT images. The CT pro-
tocol was changed during the study period, from diagnostic
CE CT to low-dose CT. Thus, attenuation correction of the
PET signal was performed using diagnostic CE CT (120 kV,
240 reference mAs) in 11/215 patients and low-dose CT
(120 kVand 50 reference mAs) in 204/215.
A physician with > 2 years of PET/CTexperience and who
was blinded for clinical findings, MRI findings, and surgical
staging results reviewed all images retrospectively on a
Segami Oasis workstation. Metabolic tumor volume (MTV)
was calculated by segmenting a volume of interest (VOI) in-
cluding all putative tumor voxels with body weight standard-
ized uptake value (SUV) > 2.5. The selection of SUV thresh-
old was based on clinical experiences of SUV levels in healthy
background tissue. The mean and maximum SUV values
within this VOI, SUVmean, and SUVmax, respectively, were
also recorded in addition to the presence of increased 18F-
FDG uptake in lymph nodes (SUVmax > 2.5), interpreted as
likely LNM (PET-positive LN) (Fig. 1).
Statistical analysis
Median values with 95% confidence interval (CI) were
assessed for all imaging-derived tumor parameters.
Correlation analyses were performed using Spearman’s rank-
order correlation test, and interobserver reliability was assessed
using intraclass correlation coefficient (ICC) for continuous
variables and Fleiss kappa statistics for categorical variables.
The Mann-Whitney U test was used to analyze differences in
imaging parameters in relation to surgicopathological stage
and tumor grade. Receiver operating characteristic (ROC)
analyses were employed to compare the diagnostic perfor-
mance of the different imaging parameters for predicting
LNM, and optimal cutoff values for MTV and VMRI were
identified from the ROC curves using the Youden index.
Patient-based logistic regression analysis for prediction of
LNM was conducted for the categorized imaging variables as
well as for the detection of LNM on conventional PET/CTand
MRI reading (PET- and MRI-positive LN). Sensitivity,
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specificity, and accuracy were compared by McNemar’s test.
The prognostic value of the imaging parameters was explored
using the Kaplan-Meier with log-rank test and the Cox propor-
tional hazard model. Analyses were performed in SPSS 24.0
(IBM Corp.) and STATA 15.1 (StataCorp). The reported
p values were generated by two-sided tests and considered
significant when less than 0.05.
Results
Patients and treatment
A total of 215 patients with endometrial cancer were included
in the study (Table 1), and all patients were treated according
to the Norwegian national guidelines for endometrial cancer.
Altogether, 98% (211/215) of the patients underwent primary
surgical resection with hysterectomy and bilateral salpingo-
oophorectomy. One patient (1/215) underwent tumor
debulking without hysterectomy (grade 3, FIGO IVB); two
patients (2/215) were deemed medically ineligible for surgical
treatment (both grade 3, FIGO IVA and IVB, respectively);
and one patient (1/215) who wished to preserve fertility,
refrained from surgery (grade 1, FIGO IA). The histological
diagnoses of these four patients are based on uterine biopsies
and recorded FIGO stage on findings from diagnostic
imaging.
Pelvic lymph node dissection (PLND) was performed
in 138 patients and revealed LNM in 12% (16/138) of
the patients while paraaortic lymph node dissection
(PALND) in 43 patients revealed paraaortic LNM in
2% (1/43). Median (range) of nodes examined was 13
(1–35) for PLND and 19 (5–54) for PALND. Patients
undergoing lymphadenectomy had significantly lower
BMI, and a higher proportion of the patients had high-
grade tumors, non-endometrioid subtype, DMI; received
adjuvant treatment; and experienced disease progression
(Suppl. Table 2).
Adjuvant therapy was given in 36% (78/215) of the pa-
tients; chemotherapy in 33% (72/215), external radiation in
1% (2/215), internal radiation in 1% (2/215), and hormonal
treatment in 1% (2/215).
Fig. 1 Pelvic MRI (a–c) and
whole-body 18F-FDG PET/CT
(d–f) of a 60-year-old patient with
endometrial carcinoma, FIGO
stage IIIC (endometrioid, grade
3). a Axial oblique contrast-
enhanced T1-weighted MRI and
(b) sagittal T2-weighted MRI for
measurement of maximum tumor
diameters in three orthogonal
planes (AP, TV, and CC
diameters). c On apparent
diffusion coefficient map, the
tumor (arrow) is depicted as
hypointense indicating restricted
diffusion. d Axial and (e) frontal
18F-FDG PET/CT show the
metabolic tumor volume (MTV)
(red line shows the MTV
boundaries) in which the
maximum and mean standardized
uptake values are measured. f
Maximum intensity projection
map depicts the 18F-FDG-avid
primary tumor (white arrow) and
18F-FDG-avid pelvic metastatic
lymph nodes (black arrows)
Eur Radiol (2020) 30:2443–24532446
Interobserver reproducibility for MRI assessment
and intercorrelation between MRI and PET/CT tumor
parameters
The interobserver reliability for the MRI tumor measurements
assessed by the three readers was high with ICC (95% CI) of
0.947 (0.934–0.958) for AP diameter, 0.912 (0.879–0.935) for
TV diameter, 0.942 (0.923–0.957) for CC diameter, and 0.919
(0.897–0.937) for ADCmean. For assessment of enlarged
lymph nodes based on MRI, the agreement between the three
readers was only moderate with an overall Fleiss kappa (95%
CI) of 0.425 (0.280–0.482). In 8/215 patients, two of the MRI
readers recordedMRI-positive LN, whereas the last reader did
not. Two of these eight patients were finally stagedwith LNM.
There were strong-to-moderate positive correlations be-
tween the 18F-FDG PET/CT tumor parameters and VMRI
(r = 0.56–0.83 (range), p < 0.001 for all) while only weak neg-
ative correlations between ADCmean and the other imaging
parameters (r = − 0.38–0.43 (range), p < 0.001 for all)
(Table 2). For the subgroup of 60 patients in whom full 3D
tumor segmentation was conducted, the calculated tumor vol-
umes from the 3D method (mean of 14 ml) and the ellipsoid
method (mean of 17 ml) yielded an ICC (absolute agreement)
of 0.968 (95% CI 0.936–0.982), demonstrating an overall ex-
cellent agreement.
Association between tumor imaging parameters
and clinicopathological patient characteristics
All the F18-FDG PET/CT tumor parameters had significantly
higher primary tumor values in patients with DMI, high his-
tological grade (endometrioid grade 3), and advanced stage
(FIGO III and IV) (p ≤ 0.001 for all; Table 3). SUVmax and
MTV were also significantly higher in patients with LNM
(p = 0.04 and p < 0.001, respectively), while MTV was the
only F18-FDG PET/CT imaging parameter that was signifi-
cantly associated with CI (p = 0.003) (Table 3).
VMRI was significantly higher in patients with DMI
(p < 0.001), CI (p = 0.03), LNM (p = 0.001), high histological
grade (p < 0.001), and advanced FIGO stage (p < 0.001). Low
tumor ADCmean was significantly associated with DMI
(p < 0.001), high histological grade (p < 0.001), and advanced
FIGO stage (p = 0.03) (Table 3).
Prediction of lymph node metastases by preoperative
imaging parameters
MTVyielded the highest area under the ROC curve (AUC) for
prediction of LNM (AUC = 0.80; Fig. 2). The AUC for
predicting LNM was significantly higher for MTV compared
with that for VMRI, yielding the second highest AUCs (p =
0.03). Based on the ROC curves (Fig. 2), the optimal cutoff
values for MTVand VMRI were 27 ml and 10 ml, respectively.
Using these cutoff values for predicting LNM, MTV > 27 ml
yielded significantly higher specificity (p < 0.001) and
Table 1 Patient characteristics and surgicopathological findings in 215
endometrial cancer patients
Age, mean (range) 68 (30–90)
BMI, mean (range) 29 (16–53)
Postmenopausal, n (%) 204 (95%)
Risk status* from preoperative biopsy/curettage
Low risk 144 (67%)
High risk 71 (33%)
FIGO stage†, n (%)
Stage IA 123 (57%)
Stage IB 48 (22%)
Stage II 18 (8%)
Stage IIIA 3 (1%)
Stage IIIB 4 (2%)
Stage IIIC1 12 (6%)
Stage IIIC2 1 (1%)
Stage IVA 1 (1%)
Stage IVB 5 (2%)




Histologic grade† (endometrioid only), n (%)
Grade 1 98 (57%)
Grade 2 42 (24%)
Grade 3 27 (16%)
Missing 5 (3%)
Myometrial invasion†, n (%)
< 50% 140 (65%)
≥ 50% 72 (34%)
Missing 3 (1%)
Cervical stroma invasion†, n (%)
No 180 (84%)
Yes 31 (14%)
Uterus not removed 4 (2%)
Lymphadenectomy†, n (%)
Pelvic 95 (44%)
Pelvic + paraaortic 43 (20%)
No 77 (36%)
Lymph node metastases†, n (%)
No 122 (57%)
Yes 16 (7%)
Not investigated 77 (36%)
BMI, body mass index; FIGO, International Federation of Gynecology
and Obstetrics
*Low risk: endometrioid subtype grades 1 and 2; high risk: endometrioid
subtype grade 3 and non-endometrioid subtype
† Findings from surgical and pathological staging
Eur Radiol (2020) 30:2443–2453 2447
accuracy (p < 0.001) while similar sensitivity (p = 1.00) to
VMRI > 10 ml (Table 4). Furthermore, MTV > 27 ml yielded
an odds ratio (OR) of 12.2 (p < 0.001), whereas VMRI > 10 ml
yielded an OR of 9.7 (p = 0.003) for prediction of LNM
(Table 4).
The sensitivity for PET-positive LN was higher than for
MRI-positive LN (50% vs 31%, respectively), although not
statistically significant (p = 0.25) (Table 4). The specificity
and accuracy were similar for PET- and MRI-positive LN,
but PET-positive LN yielded an OR of 12.6 (p < 0.001) while
MRI-positive LN yielded an OR of 7.5 (p = 0.003) (Table 4).
In multivariate analyses including imaging variables as
well as preoperative high-risk status (endometrial biopsy/
curettage indicating endometrioid grade 3/non-endometrioid
histology vs endometrioid grades 1–2), only PET-positive LN
remained an independent significant predictor of LNM (OR =
7.8, p = 0.008), whileMTV > 27ml tended to the same (OR =
4.5, p = 0.10) (Table 4).
Stratifying patients according toMTV >/≤ 27ml resulted in
a false positive rate of 26% (32/122) and a false negative rate
of 19% (3/16) in predicting LNM. Corresponding figures
when based on PET-positive LN yielded a smaller false pos-
itive rate of 7% (9/122), however, with a much higher false
negative rate of 50% (8/16). Among patients surgically staged
with LNM, 69% (11/16) were assessed as LN negative on
PET and/or MRI. Applying the volume cutoff values to this
patient subgroup demonstrated MTV > 27 ml in 73% (8/11)
and VMRI > 10 ml in 82% (9/11).
Combining lymph node visual assessment on PET and
MTV >/≤ 27 ml in a unified prediction model yielded similar
diagnostic performance metrics compared with that of MTV
> 27 ml alone (Suppl. Fig. 1).
Prediction of progression-free survival
by preoperative imaging parameters
In total, 30 out of the 215 (14%) patients experienced progres-
sion. Among these, eleven patients received adjuvant
chemotherapy and three patients (with inoperable disease)
had primary chemotherapy. Hormonal treatment was given
to two of the 30 patients, one as primary treatment (due to
fertility wishes) and one as adjuvant treatment. Patients with
higher MTVand with PET-positive LN and MRI-positive LN
had significantly reduced PFS with univariate hazard ratios
(HRs) of 1.003 (p = 0.017), 4.0 (p = 0.001), and 5.6
(p < 0.001), respectively. High VMRI was not significantly as-
sociated with reduced survival (Table 5). When adjusting for
preoperative high-risk status and patient age, PET- and MRI-
positive LN remained significantly associated with reduced
survival (HR = 3.3, p = 0.004; and HR = 4.3, p = 0.001, re-
spectively), while MTV was not (Table 5).
When stratifying according to the proposed volume cutoff
values for prediction of LNM, both MTV > 27 ml and VMRI
> 10 ml were significantly associated with reduced
progression-free survival (Fig. 3), both in the univariate anal-
yses (HR = 3.6, p < 0.001; and HR = 4.1, p = 0.001, respec-
tively) and in multivariate analyses (HR = 2.7, p = 0.010;
and HR = 3.2, p = 0.006, respectively) (Table 5).
In patients surgicopathologically staged as FIGO I–II (n =
189), large MTV, VMRI > 10 ml, and MRI-positive LN tended
to predict poor PFS with HRs of 1.009 (p = 0.07), 2.2 (p =
0.09), and 3.9 (p = 0.07), respectively (Suppl. Table 3). For
patients with FIGO stages III–IV (n = 26), none of the imaging
markers significantly predicted survival (Suppl. Table 3).
Among patients primary staged as FIGO I–II, 10% (19/189)
eventually developed progression; in these nineteen patients,
37% (7/19) had MTV > 27 ml and 58% (11/19) had VMRI
> 10 ml.
Discussion
Preoperative identification of LNM and high-risk disease is
critical for better tailoring of surgical procedure and adjuvant
therapy in endometrial cancer patients. In this large
population-based study, we demonstrate that imaging markers
Table 2 Median (range) values and correlation (Spearman’s rho, r) between 18F-FDG PET/CT and MRI tumor markers analyzed in a cohort of 215
endometrial cancer patients
SUVmax SUVmean MTV VMRI ADCmean
Median (range) 14.1 (2.8–39.0) 5.4 (2.3–15.2) 16 (0–744) ml 9 (0–795) ml 779 (383–1665) × 10−6 mm2/s
r (n) r (n) r (n) r (n) r (n)
SUVmax 1 (200) 0.90* (199) 0.72* (200) 0.56* (200) − 0.40* (192)
SUVmean - 1 (199) 0.70* (199) 0.61* (199) − 0.38* (191)
MTV - - 1 (215) 0.83* (215) − 0.43* (203)
VMRI - - - 1 (215) − 0.38* (203)
ADCmean - - - - 1 (203)
SUV, standardized uptake value; MTV, metabolic tumor volume; VMRI, tumor volume from MRI; ADC, apparent diffusion coefficient
*Correlation is significant, p < 0.001 (2-tailed)
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from 18F-FDG PET/CT outperformMRI markers for the pre-
diction of LNM. To our knowledge, this is the first study
comparing metabolic tumor volume and LNM detected on
18F-FDG PET/CT to anatomical tumor volume and LNM
detected on MRI, in a large cohort of endometrial cancer
patients.
This study demonstrates that conventional PET/CT reading
has high specificity (93%), but limitations in sensitivity (50%)
for prediction of LNM. The sensitivity in this study is in the
lower range of that reported in previous PET/CT studies on
endometrial cancer [19–22, 24]. However, several of these
previous studies comprise patient cohorts with higher percent-
age of patients having advanced stage and with higher preva-
lence of LNM compared with the present study, which may
partly explain the differences in diagnostic performance met-
rics achieved for the different cohorts. Interestingly, when
employing MTV > 27 ml as a cutoff value, higher sensitivity
(81%), although at the cost of lower specificity (74%), was
achieved. While conventional PET/CT reading has well-
known limitations in diagnosing micrometastases, high
MTV may pose an increased risk of micrometastases which
is likely to explain the higher sensitivity observed for MTV >
27 ml compared with the conventional PET/CT reading for
prediction of LNM.
In a recent large study comprising of 287 endometrial can-
cer patients preoperatively staged by both PET/CT and MRI,
LNM detection based on PET/CT yielded better sensitivity
Table 4 Sensitivity, specificity, PPV, NPV, accuracy, and OR for
prediction of pelvic lymph node metastases in n = 138 endometrial
cancer patients subjected to lymphadenectomy, by MTV larger than
27 ml, VMRI larger than 10 ml, and detected lymph nodes (LN) from
conventional 18F FDG PET/CT reading and MRI reading
MTV > 27 ml* VMRI > 10 ml* PET-positive LN MRI-positive LN
Sensitivity (%, no. of patients) 81 (13/16) 88 (14/16) p = 1.00§ 50 (8/16) 31 (5/16) p = 0.25§
Specificity (%, no. of patients) 74 (90/122) 58 (71/122) p < 0.001§ 93(113/122) 94 (115/122) p = 0.77§
PPV (%) 29 22 47 42
NPV (%) 97 97 93 91
Accuracy (%) 75 62 p < 0.001§ 88 87 p = 1.00§
Univariate OR (95% CI) 12.2 (3.3–45.6) 9.7 (2.1–44.8) 12.6 (3.8–41.4) 7.5 (2.0–27.5)
p < 0.001† p = 0.003† p < 0.001† p = 0.003†
Multivariate OR‡ (95% CI) 4.5 (0.7–27.6) 2.4 (0.3–20.3) 7.8 (1.7–35.1) 1.5 (0.2–9.1)
p = 0.10† p = 0.41† p = 0.008† p = 0.67†
Significant p values are given in italics
PPV, positive predictive value;NPV, negative predictive value;OR, odds ratio;MTV, metabolic tumor volume; VMRI, tumor volumemeasured fromMRI;
CI, confidence interval
*Optimal cutoff value for MTV and VMRI based on the receiver operating characteristic analysis (Youden’s index) for prediction of lymph node
metastases
†Binary logistic regression analyses
‡Adjusted for risk status based on preoperative endometrial biopsy/curettage indicating endometrioid grade 3 or non-endometrioid histology, in addition
to the listed imaging variables
§McNemar’s test (p, two-tailed) for comparison of sensitivity, specificity, and accuracy between MTV > 27 ml versus VMRI > 10 ml and PET-positive
LN versus MRI-positive LN, respectively
Fig. 2 Receiver operating characteristic (ROC) curves for prediction of
lymph node metastases for 18F-FDG PET/CT- and MRI-based tumor
markers. ADCmean, mean tumor apparent diffusion coefficient; MI
≥ 50%, MRI-assessed myometrial invasion ≥ 50%; MRI-positive lymph
nodes (LN), enlarged LN based on conventional MRI reading (short-axis
diameter ≥ 10 mm); MTV, metabolic tumor volume; SUVmax, maximum
tumor standardized uptake value; SUVmean, mean tumor standardized
uptake value; PET-positive LN, LN with SUVmax ≥ 2.5; VMRI, MRI-
based tumor volume. p value refers to test of equal AUC values across
tumor imaging parameters
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than MRI (70% vs 34%) [24]. The same tendency was ob-
served in the present study, with sensitivity of 50% versus
31% for PET- and MRI-positive LN, respectively (Table 4).
However, we also found that MTV > 27 ml yield significantly
higher specificity, accuracy, and odds ratios for prediction of
LNM compared with VMRI > 10 ml, suggesting that MTV
measurement may represent a valuable adjunct to the conven-
tional PET/CT reading in endometrial cancer.
For prediction of survival, we found that high MTV, PET-
positive LN, and MRI-positive LN significantly predicted re-
duced progression-free survival whereas high VMRI did not.
Interestingly, when stratifying MTV and VMRI according to
the proposed cutoff values, both VMRI > 10 ml and MTV
> 27 ml were significantly associated with reduced
progression-free survival. This is in line with previous endo-
metrial cancer studies reporting that large tumor size measured
by MRI [25] and large MTV at 18F-FDG PET/CT [26] both
are linked to reduced survival. To our knowledge, this is, how-
ever, the first study to compare VMRI and MTV in a large
patient cohort and to show that the negative prognostic impact
of large MTV may be even higher than that of large VMRI in
endometrial cancer.
Several risk models for prediction of LNM have been pro-
posed [7–12], and in a study from 2015, Koskas et al [13]
evaluated ten models in an independent patient cohort and
found that the best model (based on CA125 and MRI findings
[12]) yielded an AUC of 0.76 and a false negative rate of 4%.
The present study shows that a riskmodel based onMTV cutoff
value of 27 ml alone will yield a higher AUC of 0.80 for
prediction of LNM, however with a higher false negative rate
of 19%.Whether a combination ofMTVand other preoperative
clinical/biochemical/molecular markers may yield even better
prediction of LNM remains to be explored in future studies and
needs to be validated in independent patient cohorts.
This study has some limitations. First, the imaging proto-
cols at our institution have been revised during the study peri-
od. MRI was performed on two different scanners (1.5 and
3 T), and the CT protocol used for attenuation correction of
the PET images was changed. The 3-T MRI protocol was,
however, intentionally set up to be very similar to the 1.5-T
protocol (Suppl. Table 1). Also, the impact on PET attenuation
correction due to differences in CT protocols is assumed to be
minimal. This assumption is supported by the FDG PET/CT
procedure guidelines for tumor imaging [27] which state that
contrast agents only minimally affect the SUV quantification.
Also, when excluding the 11 patients (with attenuation correc-
tion based on diagnostic CT) in the analyses in the present
study, all significant findings were reproduced, supporting that
Table 5 Cox regression analyses
of preoperative 18F-FDG PET/
CT and MRI markers for predic-
tion of progression-free survival
in 215 patients with endometrial
cancer
Imaging variables Univariate HR (95% CI) p Adjusted† HR (95% CI) p
MTV 1.003 (1.001–1.006) 0.017 1.002 (0.999–1.005) 0.13
MTV > 27 ml 3.6 (1.8–7.4) < 0.001 2.7 (1.3–5.7) 0.010
PET-positive LN 4.0 (1.8–9.1) 0.001 3.3 (1.5–7.5) 0.004
VMRI 1.002 (0.999–1.005) 0.18 - -
VMRI > 10 ml 4.1 (1.8–9.2) 0.001 3.2 (1.4–7.3) 0.006
MRI-positive LN 5.6 (2.5–12.7) < 0.001 4.3 (1.9–10.0) 0.001
Significant p values are given in italics
HR, hazard ratio; CI, confidence interval; MTV, metabolic tumor volume; VMRI, tumor volume from MRI
†Adjusted for risk status based on preoperative endometrial biopsy/curettage indicating endometrioid grade 3 or
non-endometrioid histology and patient age at primary treatment
Fig. 3 Kaplan-Meier survival
curves depicting progression-free
survival according to a 18F-FDG
PET/CT-based metabolic tumor
volume (MTV) ≤ 27 versus
> 27 ml and b MRI-based tumor
volume (VMRI) ≤ 10 versus
> 10 ml. P values refer to the log-
rank test. For each category:
number of cases (number of cases
with progression)
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the change in attenuation correction protocol has not substan-
tially biased our results. Secondly, the MRI tumor volumes
were estimated assuming the tumor shape of an ellipsoid,
which might not be the case for all tumors. However, given
an ICC of 0.968 between 3DMRI tumor segmentation method
and the ellipsoid method in the subgroup of 60 patients, it
seems highly unlikely that the employedmethod for estimation
of MRI tumor volumes has substantially biased our results.
In conclusion, this study found that imaging markers from
18F-FDG PET/CToutperformMRImarkers for the prediction
of LNM in endometrial cancer patients. MTV > 27 ml yielded
a high diagnostic performance for predicting LNM and ag-
gressive disease and represents a promising supplement to
conventional PET/CT reading in endometrial cancer.
However, the promising role of PET/CT-derived biomarkers
needs to be confirmed in independent cohorts and evaluated in
combination with other preoperative biomarkers and novel
emerging techniques such as SLND, in order to define the
added value of PET/CT for better prediction of LNM and
aggressive disease in endometrial cancer.
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